Release Date: January 30, 2026
Expiration Date: January 30, 2027
Activity Overview
Welcome to this OncoByte Adaptive Learning Pathway!
Each OncoByte video consists of a 5-minute presentation delivered by our expert faculty on a key foundational topic regarding the management of chronic graft-vs-host disease (GVHD).
Prior to watching an OncoByte, you will be asked a question on the topic to assess your baseline knowledge and confidence. If you answer the question correctly and confidently, you will continue to the next topic. If you answer the question incorrectly or without high confidence, you will continue to the OncoByte video.
After proceeding through your customized learning pathway, you will be led to a panel discussion where our expert faculty will help you synthesize the latest information and data on chronic GVHD and incorporate best practices for routine management.
Target Audience
This educational activity is directed toward physicians, hematologists, nurses, nurse practitioners, physician assistants, pharmacists, and other health care providers involved in the diagnosis and treatment of GVHD.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the mechanism of action for current and emerging therapies being evaluated for the prophylaxis and treatment of GVHD
- Analyze efficacy and safety from recent and ongoing clinical trials evaluating targeted therapies for the treatment of GVHD
- Integrate current evidence and treatment guidelines to personalize care for GVHD
- Utilize strategies to readily identify and optimally manage treatment-related toxicities in patients with GVHD
Corey Cutler, MD, MPH, FRCP(C)
Director of Stem Cell Transplantation Program
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: CareDx, CSL Behring, Incyte, Sanofi, Syndax; Royalty of Patent Benefits: UpToDate; Ownership in privately help companies: Cimeio, Orca Bio, Oxford Immune Algorithmics
Amin M. Alousi, MD
Professor of Medicine
Inpatient Medical Director
Director, Multidiscipline GVHD Clinic and Research Program
Department of Stem Cell Transplantation and Cellular Therapy
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Incyte, Sanofi; Grant/Research Funding (to institution): Incyte; Adjudicator: Orca Bio; DSMB: Chronic GVHD Consortium
Mehdi Hamadani, MD
Professor of Medicine
Section Chief of Hematologic Malignancies
Scientific Director, CIBMTR
Division of Hematology & Oncology
Co-Associate Director of Clinical Research
Cancer Center Scholar Endowed Chair
Froedtert & Medical College of Wisconsin Clinical Cancer
Center
Medical College of Wisconsin
Milwaukee, WI
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: ADC Therapeutics, AstraZeneca, Autolus, BeiGene, Bristol Myers Squibb, Byondis, Caribou, Daiichi Sankyo, Forte Biosciences, Kite, Sobi; Grant/Research Funding: ADC Therapeutics, Spectrum Pharmaceuticals
Anna Sureda, MD, PhD
Head of the Hematology Department and Hematopoietic Stem Cell
Transplant Programme
Institut Català d'Oncologia
Hospital Duran i Reynals
Granvia de l'Hospitalet
Barcelona, Spain
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alexion, Amgen, Bristol Myers Squibb/Celgene, Gilead, Janssen, Kite, Merck Sharp & Dohme, Novartis, Roche, Sanofi, Takeda; Grant/Research Funding: Bristol Myers Squibb/Celgene, Takeda; Other: president of the GETH-TC, president of the EBMT
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
